Evan Rachlin, MD

Evan Rachlin, Co-Founder and Managing Partner of Ascenta Capital, focuses on investing in development-stage biotechnology companies. Previously, he served as a Managing Director at Blackstone Life Sciences and Head of Strategy at Moderna. Earlier in his career, Evan held roles at Bain Capital Ventures, McKinsey & Company, and Pfizer. He currently serves on the boards of Iambic Therapeutics, Cardurion Pharmaceuticals, OrsoBio, and Alpha-9 Oncology. Evan earned his AB in Biochemistry and Japanese, magna cum laude, from Harvard University and his MD from Harvard Medical School. He also serves on the Boston Children’s Hospital Trust.